Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse (PROLAPSE)
Primary Purpose
Uterovaginal Prolapse, Hysteropexy
Status
Unknown status
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
patient who undergo laparoscopic/robotic-assisted hysteropexy
patient who undergo vaginal hysterectomy
Sponsored by
About this trial
This is an interventional treatment trial for Uterovaginal Prolapse
Eligibility Criteria
Inclusion Criteria:
- POP-Q stage II with symptom or POP-Q III, IV regardless of symptom
Exclusion Criteria:
- abnormal uterine bleeding
- significantly enlarged fibroid uterus
- postmenopausal uterine bleeding
- endometrial pathology
- on tamexifen
- concomitant medical problems precluding general anesthesia or surgery
- damaged agreement ability
Sites / Locations
- Seoul National Univesity Bundang HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
laparoscopic/robotic-assisted hysteropexy
vaginal hysterectomy
Arm Description
patient who undergo laparoscopic/robotic-assisted hysteropexy
patient who undergo vaginal hysterectomy
Outcomes
Primary Outcome Measures
recurrence rate (%)
recurrence rate(%) of uterovaginal prolapse POP-Q stage II-IV in postoperative 1 year
Secondary Outcome Measures
Full Information
NCT ID
NCT02877407
First Posted
August 16, 2016
Last Updated
August 24, 2016
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02877407
Brief Title
Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse
Acronym
PROLAPSE
Official Title
A Randomized Controlled Study of Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse
Study Type
Interventional
2. Study Status
Record Verification Date
August 2016
Overall Recruitment Status
Unknown status
Study Start Date
June 2016 (undefined)
Primary Completion Date
June 2017 (Anticipated)
Study Completion Date
June 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
4. Oversight
5. Study Description
Brief Summary
objective: aimed to compare laparoscopic/robot-assisted hysteropexy with vaginal hysterectomy for uterine prolapse
prospective randomized clinical trial
patient
60yrs or more women and
POP-Q stage II with symptom or POP-Q III, IV regardless of symptom
number of patient: 146
randomize: laparoscopic/robot-assisted hysteropexy vs. hysterectomy
follow up: postoperative 1 year
primary endpoint: recurrence rate
recurrence of uterovaginal prolapse POP-Q stage II-IV
recurrence of associated symptom
secondary endpoint
postoperative 1 year QOL, degree of satisfaction evaluation
operative time, estimated blood loss
hospitalization period, postoperative pain, return to normal activity
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterovaginal Prolapse, Hysteropexy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
146 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
laparoscopic/robotic-assisted hysteropexy
Arm Type
Other
Arm Description
patient who undergo laparoscopic/robotic-assisted hysteropexy
Arm Title
vaginal hysterectomy
Arm Type
Other
Arm Description
patient who undergo vaginal hysterectomy
Intervention Type
Procedure
Intervention Name(s)
patient who undergo laparoscopic/robotic-assisted hysteropexy
Intervention Type
Procedure
Intervention Name(s)
patient who undergo vaginal hysterectomy
Primary Outcome Measure Information:
Title
recurrence rate (%)
Description
recurrence rate(%) of uterovaginal prolapse POP-Q stage II-IV in postoperative 1 year
Time Frame
postoperative 1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
POP-Q stage II with symptom or POP-Q III, IV regardless of symptom
Exclusion Criteria:
abnormal uterine bleeding
significantly enlarged fibroid uterus
postmenopausal uterine bleeding
endometrial pathology
on tamexifen
concomitant medical problems precluding general anesthesia or surgery
damaged agreement ability
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dong Hun Suh, associate professor
Email
sdhwcj@naver.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dong Hun Suh, associate professor
Organizational Affiliation
Seoul National University Bundang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National Univesity Bundang Hospital
City
Seongnam-si
State/Province
Kyeonggi-do
ZIP/Postal Code
13620
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dong Hun Suh, associate professor
12. IPD Sharing Statement
Learn more about this trial
Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse
We'll reach out to this number within 24 hrs